Plain-English translation of NCT06569680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help people with extranodal marginal zone lymphoma (a rare type of blood cancer affecting tissues outside lymph nodes). Researchers want to find out whether this medication works better than current treatments and whether it is safe to use. You would receive the medication over about 3.5 years if you join.
Extranodal marginal zone lymphoma is a rare cancer, and doctors want to find better treatment options for patients who have never been treated before. This trial will help determine whether this new medication can improve outcomes for people with this specific type of lymphoma.
You likely qualify if…
You likely don't qualify if…
You would receive the new medication in cycles over 8 treatment periods, with each cycle lasting 21 days. Your participation would last about 3.5 years total, during which you would have regular clinic visits to receive the medication, have blood tests and imaging scans to monitor how your lymphoma responds, and report any side effects. The study team will track whether the medication helps shrink your cancer and whether it is safe and well-tolerated.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States